Table 3.
Univariate and multivariate analyses of the relationship of CD44+/CD24-/low tumor cells to disease-free survival
| Variable |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| CD44+/CD24-/low tumor cells | ||||||
| High |
2.144 |
1.321-3.479 |
0.002 |
1.963 |
1.163-3.313 |
0.012 |
| Low |
1.000 |
|
|
1.000 |
|
|
| ER status | ||||||
| Positive |
0.826 |
0.524-1.304 |
0.412 |
1.425 |
0.731-2.776 |
0.298 |
| Negative |
1.000 |
|
|
1.000 |
|
|
| PR status | ||||||
| Positive |
0.500 |
0.312–0.800 |
0.004 |
0.192 |
0.088–0.420 |
0.001 |
| Negative |
1.000 |
|
|
1.000 |
|
|
| Her2 status | ||||||
| Positive |
0.966 |
0.614–1.521 |
0.882 |
0.692 |
0.317–1.513 |
0.357 |
| Negative |
1.000 |
|
|
1.000 |
|
|
| Basal-like feature* | ||||||
| Present |
2.731 |
0.461-1.393 |
0.007 |
3.902 |
1.402-10.859 |
0.009 |
| Absent |
1.000 |
|
|
1.000 |
|
|
| TNM stage | ||||||
| Stage III/IV |
1.989 |
0.814–2.626 |
0.029 |
1.820 |
1.051–3.151 |
0.033 |
| Stage I/II |
1.000 |
|
|
1.000 |
|
|
| Lymph node involvement | ||||||
| Absent |
0.724 |
0.427-1.227 |
0.230 |
1.081 |
0.540-2.164 |
0.827 |
| Present |
1.000 |
|
|
1.000 |
|
|
| Age (years) | ||||||
| ≥ 50 |
1.047 |
0.681–1.610 |
0.883 |
1.062 |
0.627–1.799 |
0.822 |
| < 50 | 1.000 | 1.000 | ||||
Abbreviations: HR, hazard ratio estimated from Cox proportional hazard regression model; CI, confidence interval of the estimated HR. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
* Immunohistochemically negative for both SR and Her2.